Published May 29, 2014
As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus. An online publication this month in Hepatology is the first to report real-time tracking of viral decay in the liver and blood in 15 patients with HCV.
Led by Andrew H. Talal, UB professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition and corresponding author, the study is the first to trace in real-time how the drug telaprevir inhibits viral replication in the liver and how it clears HCV from infected cells and plasma of infected patients.
The study was sponsored by Vertex Pharmaceuticals, which makes telaprevir, an HCV protease inhibitor.
“Our findings begin to define for how long patients may need to be treated in order to achieve viral eradication,” Talal says.
“There has been no precise definition of the duration of treatment based upon serial measurements of the virus in the liver,” he says. “This is the first time that serial measurements in the liver have been performed during antiviral therapy.”
In previous studies, a more invasive procedure — core needle biopsy — was used to sample the liver in HCV infection. In the current study, fine needle aspiration was used, a method that is better tolerated by patients and allows for repeated sampling at more time points than core needle biopsy.
“Fine needle aspiration enables us to sample the liver repeatedly during the course of treatment to better understand what’s happening with the virus, how these drugs work and how to tailor therapy to the patient,” Talal explains.
In the study, conducted at Weill Cornell Medical College in New York City, 15 patients with chronic HCV infection were treated with telaprevir-based triple therapy (consisting of telaprevir/pegylated interferon alfa/ribavirin), an HCV treatment regimen approved by the Food and Drug Administration in 2011.
Fine needle aspiration of the liver was performed before treatment on all 15 patients and at these intervals following treatment: 10 hours, on days 4 and 15, and at week 8. Viral kinetics, resistance patterns, drug concentrations and host transcription profiles were measured.
Of particular interest were the study’s findings regarding the rate of decay for viral ribonucleic acid (RNA), an indicator of how quickly the virus is being eradicated.
“We found that HCV RNA decay in the liver lagged behind that in the peripheral blood, which has implications for how long the virus may persist in the body and the possible duration of treatment needed,” says Talal.
They also found higher levels of the drug in blood than in the liver.
“These findings can affect the duration of therapy,” he says, adding they also can help identify when drug-resistant variants of the virus emerge in blood and in the liver.
The findings also may have relevance to the development of other methods of treating HCV, such as vaccines that could be used to control the infection, he adds.
Talal conducts research on HCV in the Clinical and Translational Research Center in the School of Medicine and Biomedical Sciences, and sees patients as a physician with UBMD, the physician practice plan of the UB medical school. Talal has had additional research projects funded by Vertex Pharmaceuticals.
In addition to Talal, who has an adjunct appointment at Weill Cornell, co-authors of the paper are Rositsa B. Dimova, research assistant professor in the UB departments of Medicine and Biostatistics; Marija Zeremski, senior research associate at Weill Cornell and research assistant professor of medicine at UB; Christine M. Cervini, staff associate in medicine, and Ira M. Jacobson, chief of the Division of Gastroenterology and Hepatology, both of Weill Cornell; Eileen Z. Zhang, Min Jiang, Marina S. Penney, James C. Sullivan, Martyn C. Botfield, Ananthsrinivas Chakilam and Rishikesh Sawant, all of Vertex Pharmaceuticals; and Ann D. Kwong, of InnovaTID Pharmaceuticals, formerly of Vertex Pharmaceuticals. Jacobson has served as a paid consultant to Vertex.